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Practically all circulating blood cells migrate 
through the skin. This process is accelerated dur-
ing the acute inflammatory reaction where the 
stimuli for diapedesis and chemotaxis of granulo-
cytes and macrophages are reasonably well under-
stood. The same cannot be said for the cells 
involving the lymphoid series. Despite the fact that 
many dermatologic disorders are associated with 
lymphocytic infiltrates , only a few studies have 
been initiated to determine to what extent lympho-
cytes migrate through normal skin and which of 
the known lymphocyte sub populations playa role 
in different cutaneous diseases . Since it is gener-
ally believed that lymphocytes seen in the skin are 
of hematogenous rather than of local origin, the 
distribution of cells infiltrating the skin may 
reflect the percentages present in circulating 
blood. Indeed, available observations have proved 
this assumption to be partially correct. Thus, in 
the case of B-Iymphocytes where subpopulations 
can be identified by virtue of various classes of 
surface-bound immunoglobulin , at least one ob-
server has reported that patients with allergic 
contact dermatitis have a predominance of IgD-
coated lymphocytes, patients with atopic dermati-
tis have an increase in IgE-bearing lymphocytes , 
and subjects with drug reactions tend to augment 
both IgD and IgE positive cells in the peripheral 
blood as well as in their skin lesions [1]. However, 
it is dangerous to assume that in all pathologic 
states tissue lymphocytes have the same distribu-
tion as those in the blood; the cells may be 
selectively retained locally as a consequence of 
their surface or other functional properties, and 
hyperplastic or neoplastic proliferation may take 
place in tissues independent of stimuli affecting 
the cells in the bone marrow or circulating blood . 
Unfortunately, the facility with which various 
sub populations of B-Iymphocytes can be identified 
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in extravascular sites has not yet been extended to 
the T-cell series [2-4] . The recognition of T -cells in 
tissues still depends largely on a process of exclu-
sion. This is probably the reason why the Sezary 
cell, which retains its characteristic morphology in 
lymph nodes , skin, and blood, has aroused an 
unusual degree of interest during the past two 
years. The Sezary cell was first described in 1938 as 
an atypical mononuclear cell in the blood of 
patients with erythroderma and other manifesta-
tions of far advanced mycosis fungoides (MF) [5]. 
Cursory examination of a routine blood smear by 
an unaware hematologist may lead to the diagnosis 
of chronic lymphocytic leukemia (CLL). At a time 
when it became apparent that circulating lympho-
cytes of the vast majority of patients with CLL 
were B-Iymphocytes, it was surprising to find a 
patient whose cells did not have the surface 
properties of these thymus-independent cells [6]. 
The possibility that the abnormal cells represented 
monocytes was eliminated by the demonstration 
that they were nonadherent, nonphagocytic, and 
devoid of receptors for complement [7]. These 
initial observations , made more than three years 
ago , led to a series of studies that established the 
Sezary cell to be a lymphocyte with properties of 
the thymus-dependent cell line, which in some 
instances could be shown to have undergone neo-
plastic transformation. Since the results of these 
studies have been the subject of many publications 
by ourselves and others [8,9], only the salient 
features will be summarized here, while their 
significance will be considered in the light of 
current knowledge in the fields of cellular immu-
nology and immunodermatology. With the excep-
tion of 3 patients with a florid Sezary syndrome 
(SS) who were referred by private practitioners, all 
patients were diagnosed in the Department of 
Dermatology at New York University by means of 
clinical observations as well as skin and lymph 
node biopsies. Eight of the 40 patients studied were 
considered to have SS while the remainder carried 
a diagnosis of MF in various stages of severity . 
THE SEZARY CELL 
The cell is now defined as a large (12-14 J.L) or 
small (9-12 J.L) mononuclear cell of which the most 
outstanding feature is the highly convoluted nu-
cleus (Fig. 1). In contrast to Lutzner et al [9], we do 
not attribute much significance to the size of the 
cell since we have observed a mixture of large and 
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FIG. 1. Typical Sezary cells showing a convoluted but mature nucleus . Fig. a is a small cell variant. The deep 
invaginations of the cytoplasm into the nucleus may not be detectable by light microscopy ( x 11 ,000). The cell 
depicted in b has an abnormally large nucleolus (Nu) ( x 8,500) . Note that a and b are not presented at the same 
magnification. (Reprinted with permission from [6]) 
small cell variants in the blood of several patients. 
However, in small cells, the cytoplasmic invagina-
tions may be so narrow and the nucleus may be 
folded upon itself to such an extent that the clefts 
cannot be resolved by light microscopy (Fig. la). 
Thus electron microscopy (EM) of thin sections is 
often necessary to quantitate the number of Sezary 
cells in blood or lymph node specimens. As a rule, 
the cell has a conspicuous nucleolus (Fig. Ib) 
which, as is the case in normal lymphocytes , 
increases in size when the cells are more active , 
e.g. , when skin or organ infiltration is massive , or 
when spontaneous transformation takes place in 
vitro . Apart from the characteristic nucleus , we 
o 
have been particularly struck by the 80-A 
microfilaments which fill the cytoplasm of most 
Sezary cells [7 ,10] a feature often ignored by other 
investigators. Although similar filaments have 
been seen in a variety of neoplastic and tissue 
culture cells, in peritoneal macrophages, and in 
monocytoid cells of amyloid-laden lymph nodes, 
their constant presence in the Sezary lymphoid cell 
ought to provoke further thought and investigation 
(see Fig. 2a,b). In addition , the cells have an array 
of other ultrastructural abnormalities involving 
both nucleus and cytoplasm [10]. Many of these 
could be considered degenerative in nature as they 
are often seen in other abnormal cells or in cells 
maintained in vitro over prolonged periods of time. 
Quantitation of Sezary cells is best accom-
plished on specimens of " purified" lymphocytes , 
i.e., those from which monocytes have been elimi-
nated [11]. Patients with SS whose abnormal cells 
were recognized on routine blood smears were 
found to have more than 40 % Sezary cells when 
their purified lymphocytes were studied by EM. 
On the other hand, the number of Sezary cells in 
the blood of patients with MF was more variable. 
Among 32 patients analyzed in the same manner, 9 
had less than 10% Sezary cells, 10 had a range 
between 20 and 40%, whereas 3 patients whose MF 
had advanced to the infiltrating plaque stage had 
more than 40% Sezary cells in their peripheral 
blood. Whether the last 3 patients should be 
classified as having SS in the absence of ery-
throderma is debatable. 
In our laboratory, histochemical studies , such as 
the periodic acid -Schiff (PAS) reaction and acid 
phosphatase were not helpful in distinguishing 
Sezary cells from normal lymphocytes, though 
Flandrin and Daniel [12] have reported that ,a-glu-
curonidase activity may be higher in some Sezary 
cells than in normal lymphocytes. 
SURFACE PROPERTIES 
The methods used to study the surface proper-
ties of B- and T-Iymphocytes have become stan-
dard and are discussed in detail elsewhere. Suffice 
it to reiterate that Sezary cells bear no immuno-
globulin when examined by a variety of available 
methods and have no complement or Fc receptors. 
Like normal human T -lymphocytes, Sezary cells 
form spontaneous rosettes with uncoated sheep 
erythrocytes [13], although this property may be 
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FIG. 2. Se7.ary cell showing 5 cytoplasmic indentations into tangentially sectioned nucleus. Fibrillar structures are 
seen throughout the cytoplasm. The demarcated area is illustrated at higher magnification in b. Also note that this 
presumed T-Iymphocyte has numerous villous processes at one pole of the cell, a characteristic more common for 
B-Iymphocytes (x 16,000) . Fig. b shows higher magnification of the area demarcated by the rectangle in a. Arrow 
indicates cross-sections of fibrils. PR, polyribosomes ( x 70,000). (Reprinted with permission from [7]) 
lost during the course of treatment or the natural 
evolution of the disease. It must also be pointed out 
that in specimens containing a small number of 
Sezary cells, E-rosettes should be examined with 
the electron microscope to verify the morphology of 
the cell in the center of the rosette (Figs. 3, 4). In 
such specimens the absolute number of E-rosettes 
may be within normal range. Divergent results 
have been obtained when the cells were stimulated 
with phytohemagglutinin (PHA) [8,14,15 J. The 
majority of Sezary cells seem to be responsive to 
this mitogen but in 2 of our patients, whose cells 
Sept. 1976 
were tested repeatedly, responsiveness was lost 
during the course of the disease. Whether the cells 
are truly immunocompetent, i.e., whether they can 
play an initiating role in such functions as the 
graft-versus-host reaction has not been tested. It is 
noteworthy, however, that reactivity with sheep 
erythrocytes (E-rosettes) is maintained while the 
cells are undergoing mitosis following stimulation 
with PHA (Fig. 5). The presence of microfibrils 
permits identification of a Sezary cell even though 
the nucleus loses its characteristic morphology 
during blast cell transformation. In addition to 
their ability to form E-rosettes, and their response 
to PHA, the cells of a few patients have also been 
tested with antiserum specific for T -lymphocytes. 
However, since these studies could not have been 
carried out with isolated Sezary cells and no 
... 
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morphologic evidence was provided that the anti-
sera actually reacted with Sezary cells and not 
with normal T -lymphocytes in the preparation, 
these experiments must be accepted with some 
reservation. 
THYMIC FACTOR 
The recognition that the syndrome under discus-
sion is associated with a proliferation of abnormal 
T -cells made it appear relevant to examine 
whether the patients had an increase in circulating 
thymic factor (TF). The factor, a secretory product 
of the thymic epithelial cell appears to confer 
T-cell specificity on certain precursor cells. In the 
serum of young individuals, the level of TF is 
relatively high when compared with adults, and in 
subjects over the age of 50 years it becomes 
... ~ . . 
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FIG. 3. Two lymphocytes from the blood of a patient with SS having formed E-rosettes. The one on the right is a 
definite Sezary cell as judged by the shape of its nucleus . The cell on the left cannot be identified in this particular 
plane of section and could be a normal T-cell ( x 5,000). (Reprinted with permission from [7]) 
FIG. 4. Example in which a typical Sezary cell (right) has failed to form an E-rosette, whereas the cell on the left has 
formed a tight rosette (x 3,600) . (Reprinted with permission from [7]) 
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FIG. 5. Sezary cell in metaphase stage of mitosis after culture with PHA seen in the center of an E-rosette. SRBC, 
sheep red blood cells (x 7,000). 
negligible or undetectable [16]. The assays for TF 
were performed by Dr. M. Dardenne in the labora-
tory of Dr. Jean-Francois Bach, Hopital Necker, 
Paris. 
The test hinges on the observation that under 
normal circumstances, i.e., in the presence of TF, 
the formation of rosettes by mouse spleen cells and 
sheep red blood cells is inhibited by azathioprine 
(AZ) , whereas formation of rosettes by spleen cells 
obtained from thymectomized mice is relatively 
resistant to inhibition by the drug. Thus, the 
concentration of AZ required to inhibit rosette 
formation measures the amount of TF present in 
the serum under investigation. The sera of 12 
patients with MF were tested. The level of TF was 
low or undetectable in 8 of these patients, com-
mensurate with their age. However, 4 patients who 
were over 50 years old had titers of TF considered 
normal for individuals under the age of 40. Unfor-
tunately, no patients with fully developed SS were 
available at the time of testing. However, the 
possibility that the results obtained on the 4 
patients mentioned indicate a pathologically ele-
vated level of TF in patients with MF is intriguing. 
Whether these data are truly significant awaits 
additional studies. 
DISCUSSION 
The recognition of the Sezary cell as a variant of 
a T -lymphocyte provokes a number of questions: 
(1) Are all cutaneous lymphoproliferative disorders 
of T -cell origin? The answer to this question may 
turn out to be affirmative not only because T -cells 
playa predominant role in skin lesions such as the 
delayed hypersensitivity reaction, but also because 
B-cell neoplasms like multiple myeloma or eLL 
rarely affect cutaneous tissues. (2) Where do the 
cells originate? There seems to be little doubt that 
Sezary cells arise in lymphoid tissue rather than in 
the bone marrow. In several of our patients, lymph 
node involvement was seen before the cells were 
found in circulating blood (Figs 6, 7), and it is 
generally felt that Sezary cells rarely invade the 
medullary cavity until late in the disease. More-
over, replacement of hematopoietic tissue by 
Sezary cells-as is the case with B-cell neoplasms 
-has not been encountered. (3) Are Sezary cells 
malignant? Our answer to this question would be 
affirmative. A cell with an abnormal appearance 
which often shows an abnormal karyotype 
[8,9,17,18] and appears to invade normal tissue 
must be considered neoplastic. However, it is not 
yet known whether the cell is malignant from the 
outset, i.e., when the cell is found in the uncom-
plicated lesions of MF or whether it develops 
neoplastic features when it de differentiates as a 
result of an unknown continuous stimulus which 
gives rise to the disease. (4) To what extent is the 
information gained from these studies relevant to 
the treatment of patients with SS or MF (for 
review see [19])? It is already known that some 
available chemotherapeutic agents are more effec-
tive in the treatment of T-cell than B-cell disorders 
[20]. Undoubtedly new agents will be developed in 
the future directed against the specific surface 
properties of the cells concerned. Moreover, if the 
cells carry T-cell antigens, treatment with specific 
anti-T-cell antisera may be efficacious. A different 
approach, leukapheresis, has been carried out in a 
patient with a high level of circulating Sezary cells 
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FIG. 6. Infiltration of lymph node of a patient with SS; section is representative of the periphery of the node where 
the cells are smaller (x 2,500). (Reprinted with permission from [6]) 
FIG. 7. Survey picture of the center of the node showing giant nucleoli (Nu) and deep invaginations of the cytoplasm 
into nuclei (arrow) ( x 3,000). 
[21]. This procedure resulted not only in a reduc-
tion of leukocytes, but also in a diminution of the 
skin lesions [22]. Thus, this modality of treatment 
should be attempted in all patients with a leukocy-
tosis. Lastly, the thymus of patients with SS or MF 
deserves further scrutiny. Although several inv~s­
tigators have found the gland to be unremarkable 
in the few patients examined at autopsy, this 
would not preclude the possibility that in this 
disease, the epithelial cells elaborate a quantita-
tively or qualitatively abnormal product. As 
already mentioned, studies concerned with this 
question are in progress in our laboratory. If the 
thymic hormone would be shown to play any role in 
the disease, thymectomy or irradiation may offer 
some promise in the future. 
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DISCUSSION 
Hanifin: In reference to your 3 patients with Sezary 
cells and erythroderma but not proven mycosis fung-
oides, I might add 3 erythrodermatous patiel1ts we have 
seen who clearly did not have malignancy (1 had contact 
allergy and 2 had atopic dermatitis) but all had Sezary 
cells which disappeared when they had clinical remis-
sions. Have you been able to distinguish malignant and 
benign ultrastructural features (e .g., large nucleoli, etc.) 
in cells from the 2 groups? 
Zucker-Franklin: In order to answer this question one 
would have to know, first of all, whether the cells you are 
referring to were really Sezary cells and how high the 
percentage of such cells was prior to treatment. Secondly, 
one would like to know whether these patients will 
eventually develop MF, which is not a rare occurrence in 
individuals with a long history of some less-well-defined 
cutaneous lesion. The Sezary cells I have described have 
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not yet been seen in the peripheral blood in other 
diseases. And even if an occasional cell with a convoluted 
nucleus is found, such cells do not seem to make their 
appearance in large numbers. 
Epstein: Did you look for actin or myosin in 8ezary 
cells with specific antisera and immunofluorescence? I 
thought the microfibrils in the cytoplasm of these cells 
suggested they are actively motile cells. 
Zucker-Franklin: The filaments are thicker than 
those known to represent actin in platelets, monocytes, 
smooth muscle, and other mammalian cells. We have not 
used the fluorescent antibody technique to detect the 
possible presence of actin, but one attempt to "decorate" 
the fibrils with heavy meromyosin has been unsuccessful. 
Provost: What is the evidence for the Sezary cell being 
malignant? Isn't it true that normal cells may have an 
abnormal karyotype? 
Zucker-Franklin: I should hope that in 48-hr to 5 day 
PHA-stimulated cultures of lymphocytes obtained from 
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normal subjects no karyotypic abnormalities would be 
found. 
Sams: Although it is clear that the 8ezary cell is found 
in diseases other than those with erythroderma, I believe 
it is important to retain the concept of 8ezary's syndrome. 
The hematologist's first contact with this disease is when 
the cells arrive in the laboratory. The dermatologists walk 
into a room and immediately and correctly diagnose 88. 
Thus, for a patient with erythroderma and the typical 
convoluted nuclear cells that spare the bone marrow, the 
appellation of 88 is useful as it distinguishes this group 
of individuals from those with the plaque form of MF 
without erythroderma which may also have cells with a 
convoluted nucleus. 
Zucker-Franklin: Basically, I agree with you. How-
ever, I wonder whether a patient with unequivocal MF in 
the absence of generalized erythroderma, but with a very 
high percentage of 8ezary cells in the peripheral blood, 
should also be considered to have the syndrome. 
